Abstract
Twelve patients with advanced primary lung cancers associated with malignant pleural effusion were treated with intrathoracic instillation of recombinant interleukin-2 with or without in-vitro-sensitized cells. Two cases achieved complete response, and 7 partial response. The adverse effects seen in the protocol were marginal, and the protocol was well-tolerated and feasible. Furthermore, 4 cases were treated with the combination of systemic chemotherapy and adoptive immunotherapy. Of these, 3 cases responded well to the therapy and have shown a complete response for more than 20 months, indicating that adoptive immunotherapy together with chemotherapy might be a beneficial treatment for advanced lung cancer patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / pathology
-
Adenocarcinoma / therapy*
-
Adult
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
CD3 Complex / immunology
-
Carcinoma, Small Cell / pathology
-
Carcinoma, Small Cell / therapy*
-
Cells, Cultured
-
Combined Modality Therapy
-
Cytotoxicity, Immunologic
-
Female
-
Humans
-
Immunophenotyping
-
Immunotherapy, Adoptive
-
Interleukin-2 / therapeutic use*
-
Leukapheresis
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Lymphocytes / immunology
-
Lymphocytes / radiation effects
-
Male
-
Middle Aged
-
Pleural Effusion / immunology
-
Pleural Effusion / pathology
-
Recombinant Proteins / therapeutic use
Substances
-
Antibodies, Monoclonal
-
CD3 Complex
-
Interleukin-2
-
Recombinant Proteins